NCT06143423

A Clinical Trial of AP026 (TQA2226) for Injection in Adult Subjects.

A Randomized, Double-blind, Placebo-controlled Phase I Clinical Trial to Evaluate AP026 (TQA2226) for Injection in Adult Subjects After Single/Multiple Administration.

• Status: Unknown
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 74 (estimated)
• Sponsor: Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. · Industry
• Sex: All
• Age: 18 Years – 55 Years
• Healthy volunteers: Accepted

Summary

This study was a randomized, double-blind, placebo-controlled phase I clinical trial of AP026 (TQA2226) for injection in adult healthy subjects, which planned to recruit 74 healthy subjects. The main purpose was to evaluate the safety and tolerance of AP026 (TQA2226) for injection after single and multiple doses in healthy subjects.

Conditions

• Diabetes Mellitus, Type 2

Interventions

Type	Name	Description
DRUG	AP026 (TQA2226) for injection	AP026 (TQA2226) for injection is a GLP-1-FGF21-Fc bifunctional fusion protein.
DRUG	AP026 (TQA2226) for injection matching placebo	AP026 (TQA2226) for injection matching placebo is a placebo produced according to AP026 (TQA2226) for injection, and has no effect on GLP-1 and FGF21.

Timeline

• Start date: 2023-05-24
• Primary completion: 2024-06-01
• Completion: 2024-12-01
• First posted: 2023-11-22
• Last updated: 2023-11-22

Locations

1 site across 1 country: China